Complete Remission with Anti-CD20 Therapy for Unicentric, Non-HIV-Associated, Hyaline-Vascular Type, Castleman's Disease

Estephan, Fadi; Elghetany, M. Tarek; Berry, Madonna; Jones, Dennie V.

doi:10.1081/cnv-50484

Cited by 22 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, four HIV‐negative patients with Castleman's disease receiving rituximab therapy were reported. Two patients achieved remission after rituximab administration (12, 13), but two patients died as a result of Castleman's disease (14, 15).…”

Section: Discussionmentioning

confidence: 99%

Long‐term remission in HIV‐negative patients with multicentric Castleman's disease using rituximab

Ide¹,

Kawachi²,

Izumi³

et al. 2005

European J of Haematology

View full text Add to dashboard Cite

Multicentric Castleman's disease (MCD) is an indolent lymphoproliferative disorder. The pathogenesis of MCD has not been established, and its treatment remains uncertain. Several authors have described the relationship of human herpes virus type 8 (HHV-8) to MCD in human immunodeficiency virus (HIV)-positive patients. Recently, anti-CD20 monoclonal antibody (rituximab) is increasingly being used to treat HIV-positive MCD; although it is uncertain whether rituximab is effective for HIV-negative patients with MCD. To explore the benefit of rituximab for HIV-negative patients with MCD, we describe the clinical and biologic course in three HIV-negative patients with MCD, and examined the relationship of HHV-8 infection to HIV-negative MCD. Their polymerase chain reaction analyses for the HHV-8 sequence in peripheral blood were negative, and there was no relationship between HHV-8 infection and symptoms of HIV-negative MCD. Two of three patients (66%) achieved a near complete remission with no clinical symptoms due to MCD with a follow-up of 16-40 months after rituximab administration. One of the three patients presented no clinical remission of MCD after rituximab administration, although a significant decrease of inflammatory parameters was observed. These findings suggest that rituximab treatment may be an appropriate first-line therapy for HIV-negative MCD.

show abstract

Section: Discussionmentioning

confidence: 99%

Long‐term remission in HIV‐negative patients with multicentric Castleman's disease using rituximab

Ide¹,

Kawachi²,

Izumi³

et al. 2005

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…Occasionally, there may be a pattern of arborizing calcification radiating from the centre of the node 22 . The plasma cell type has a low level of CT contrast enhancement 23 . MRI findings, including heterogeneous hypointensity on T 1 ‐weighted and hyperintensity on T 2 ‐weighted images, are non‐specific 21,22 .…”

Section: Discussionmentioning

confidence: 99%

“…There has been one report of complete remission of unicentric Castleman disease with anti‐CD20 therapy, but surgical excision of unicentric tumours is believed to be the treatment of choice 23 . The number of reported cases is small, but it appears that complete resection is usually curative.…”

Section: Discussionmentioning

confidence: 99%

Surgical Outcome of Superficial and Deep Castleman Disease

Chen¹,

Liu²,

Tung³

et al. 2007

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…146 For example, use of rituximab and anti-IL-6 antibodies has been reported in patients with incompletely resected UCD. 147 In patients affected by symptomatic HHV8-negative and HIV-negative MCD, a randomized controlled trial recently compared an anti-IL-6 monoclonal antibody (siltuximab) and best supportive care to placebo and best supportive care. 148 This study demonstrated a significantly higher durable tumor Fig.…”

Section: Therapy and Prognosismentioning

confidence: 99%

Lymphoid Interstitial Pneumonia and Other Benign Lymphoid Disorders

Arcadu

Moua

et al. 2016

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Benign pulmonary lymphoid disorders include a variety of rare lymphoid abnormalities characterized by a polyclonal lymphoid infiltrate with differing histopathologic patterns and clinicoradiologic features that may overlap. Histological examination is essential to reach a correct diagnosis and to exclude alternative causes, although this task can at times prove difficult. Further studies and clinical trials are needed to provide additional insights on pathogenesis and to guide the therapeutic management of these disorders. The purpose of this article is to review the histopathological, epidemiological, and clinicoradiologic features of several benign pulmonary lymphoid disorders, including lymphoid interstitial pneumonia, follicular bronchiolitis, nodular lymphoid hyperplasia (pulmonary pseudolymphoma), inflammatory pseudotumor, immunoglobulin G4-related disease, Castleman disease, posttransplantation lymphoproliferative disease, and drug-induced lymphoid disorders.

show abstract

Complete Remission with Anti-CD20 Therapy for Unicentric, Non-HIV-Associated, Hyaline-Vascular Type, Castleman's Disease

Cited by 22 publications

References 5 publications

Long‐term remission in HIV‐negative patients with multicentric Castleman's disease using rituximab

Long‐term remission in HIV‐negative patients with multicentric Castleman's disease using rituximab

Surgical Outcome of Superficial and Deep Castleman Disease

Lymphoid Interstitial Pneumonia and Other Benign Lymphoid Disorders

Contact Info

Product

Resources

About